Thomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.
Thomas Bachelot, MD, PhD
Advertisement
Articles by Thomas Bachelot, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5